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Psoriasis patients exposed to high cumulative doses of psoralen þ ultraviolet A frequently exhibit so-called
‘‘psoralen þ ultraviolet A keratoses’’ (i.e., hyperkeratotic lesions with varying degrees of histologic atypia). The
exact causes and molecular mechanisms of psoralen þ ultraviolet A keratoses however, are not clear. We therefore
performed DNA mutational analysis of the tumor suppressor gene p53 (exons in psoralen þ ultraviolet A keratoses
from 10 long-term psoralen þ ultraviolet A-treated psoriasis patients. We detected 39 p53 mutations in 16 of 28
psoralen þ ultraviolet A keratoses (57%) and 18 Ha-ras mutations in 11 of 25 psoralen þ ultraviolet A keratoses
(44%). Of the 39 p53 mutations and 18 Ha-ras mutations, 22 (56%) and 13 (72%), respectively, were of the ultraviolet
ﬁngerprint type (C ! T or CC ! TT transitions at dipyrimidine sites); 13 (33%) and two (11%), respectively,
occurred at potential psoralen-binding sites (50-TpA, 50-TpG, or 50-TpT DNA sequences) and were potentially
psoralen þ ultraviolet A induced; two (5%) and three (17%), respectively, were of ambiguous origin (ultraviolet and/
or psoralen þ ultraviolet A); and two (5%) and none (0%), respectively, were of the ‘‘other’’ type, respectively. We
conclude that (1) the frequent mutation of p53 and Ha-ras may play a key part in the formation of at least some
psoralen þ ultraviolet A keratoses; (2) environmental and/or therapeutic ultraviolet exposure may be a major cause
of psoralen þ ultraviolet A keratosis as most Ha-ras and p53 mutations are induced by ultraviolet light; and (3)
psoralen þ ultraviolet A itself plays a smaller, though direct, role in causing these mutations.
Key words: carcinogenesis/mutagenesis/psoralen/skin cancer/ultraviolet radiation.
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Psoriasis patients exposed to high cumulative doses of
psoralen þ UVA (PUVA) are at increased risk of skin cancer,
particularly squamous cell carcinoma (SCC) (for review see
Stern et al, 1998). Long-term PUVA-treated psoriasis
patients also frequently exhibit squamous keratoses that
show varying degrees of histologic dysplasia (Abel et al,
1982; Gupta et al, 1990; Bruynzeel et al, 1991; Van Praag
et al, 1993; Lever and Farr, 1994; Buckley and Rogers,
1996; Hudson-Peacock et al, 1996). These so-called ‘‘PUVA
keratoses’’ appear on PUVA-treated body sites. They have
been described as papules, ranging in diameter from
several millimeters to about 1 cm, that have a broad base
and hyperkeratotic, scaly, warty-appearing top (Van Praag
et al, 1993). Histologically, PUVA keratoses exhibit acantho-
sis; orthokeratosis; focal parakeratosis; some apoptotic
cells in the epidermis; and often some mild, perivascular,
predominantly lymphocytic infiltrate in the papillary dermis
that slightly invades the epidermis. An estimated 50% of all
PUVA keratoses exhibit mildly atypical keratinocytes (Van
Praag et al, 1993).
PUVA keratoses are associated with an increased risk of
nonmelanoma skin cancer (Lever and Farr, 1994; Van Praag
et al, 1993). For instance, Van Praag et al (1993) established
that the relative risk for skin cancer is more than 6-fold
higher for patients with PUVA keratoses than for psoriasis
patients who also received long-term PUVA but do not have
these keratoses. They also showed that this holds true even
after adjustment for age, sex, and UVA dose. It is still not
known for certain, however, whether PUVA keratoses are
direct precursors of SCC or only indicators of increased
risk. Nor are the exact causes and molecular mechanisms
of PUVA keratoses yet known. The search for answers is
made more difficult by the fact that patients with severe
psoriasis often have additional risk factors for skin cancer,
including previous exposure to known or suspected
carcinogenic agents and treatments such as therapeutic
and/or environmental UV radiation, ionizing radiation,
methotrexate, cyclosporine, arsenic, or topical tar (for
review see Maier et al, 1996; Paul et al, 2003).
A number of molecular studies have suggested that
mutations in the p53 tumor suppressor gene and the Ha-ras
proto-oncogene, two of the genes most frequently mutated
in cancers, are involved in the formation of PUVA-
associated skin cancers. Epidemiologic DNA mutational
analyses of these genes have revealed that therapeutic and/
or environmental exposure to UV light is a significant factor
Abbreviations: BCC, basal cell carcinoma; MOP, methoxy-
psoralen; PUVA, psoralen plus UVA; SCC, squamous cell
carcinoma; SSCP, single-strand conformation polymorph-
ism.
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in the formation of PUVA-associated SCC and basal cell
carcinomas (BCC) (Nataraj et al, 1997; Wang et al, 1997;
Kreimer-Erlacher et al, 2001; Seidl et al, 2001; Stern et al,
2002). DNA sequencing analysis of the two genes in skin
cancers from PUVA-treated psoriasis patients has revealed
not only PUVA-induced mutations at psoralen-binding sites
(i.e., at or near 50-TpA, 50-TpG, or 50-TpT sequences) but
also mutations bearing the UV fingerprint (i.e., C ! T or
CC ! TT transitions at dipyrimidine DNA sequences)
(Brash et al, 1991; Rady et al, 1992; Campbell et al, 1993;
Kanjilal et al, 1993; Moles et al, 1993; Ziegler et al, 1993,
1994; Nakazawa et al, 1994; Nelson et al, 1994; Taguchi
et al, 1994; Park et al, 1996; Nomura et al, 1997).
In this light, we hypothesized that mutations in the p53
and Ha-ras genes may cause PUVA keratoses that are
predisposed to become skin cancers. To prove this, we
subjected PUVA keratoses obtained from patients at the
Department of Dermatology, Karl-Franzens University (Graz,
Austria) to DNA mutational analysis of their p53 and Ha-ras
genes in the hope of identifying potential causative factors
and determining the relation, if any, between the formation
of these keratoses and the formation of skin cancers.
Results
UV ﬁngerprint mutations occurred frequently in the p53
and Ha-ras genes of PUVA keratoses A total of 39 p53
mutations (35 mis-sense and four non-sense) were found in
16 of 28 PUVA keratoses (57%) from nine of 10 patients
(90%) (Table II). Of those 39 p53 mutations, 31 (79%)
occurred at dipyrimidine sites, and 24 (62%) were of the UV
type (23 C ! T transitions and one CC ! TT transition).
Two of the C ! T transitions occurred at dipyrimidine sites
opposite a 50TpG sequence (a potential psoralen-binding
site) (codon 322 in lesion A1 and codon 136 in lesion D1). As
this made the origin of these mutations (UV or PUVA)
ambiguous, they were considered separately in DNA
mutational analysis (Fig 1). In addition, three other mutations
(8%) occurred at 50TpG sites (one at a dipyrimidine site and
two at nondipyrimidine sites), one (3%) at a 50TpT site, and
nine (23%) at 50-TpA sites (six at dipyrimidine sites and
three at nondipyrimidine sites); all of these mutations were
potentially PUVA induced. In addition, one C ! T transition
occurred at a nondipyrimidine site, and one G ! C
transversion occurred opposite a dipyrimidine site (when
taken together, 5% of all p53 mutations observed in this
study). None of the p53 mutations detected in the PUVA
keratoses were found in normal skin tissue dissected from
the same patients. In all lesional and normal skin tissue
samples from patients I and H, however, a G ! C
transversion at codon 72 was present; and in all lesional
and normal skin tissue samples from patients D and E, an
A ! G transition at codon 213 was present. Both of these
base changes have been previously described as p53
polymorphisms (Vogel and Kopun, 1977; Cooper and
Krawczak, 1993). In addition, seven silent p53 mutations
(four of UV type, two of PUVA type, and one of other type)
were found in the PUVA keratoses.
A total of 18 Ha-ras mutations (17 mis-sense and one
non-sense) were found in 11 of 25 PUVA keratoses (44%)
from six of nine patients (66%) (Table III). Thirteen of these
18 mutations (72%) bore the UV fingerprint (C ! T
transitions at dipyrimidine sites), two (11%) at a 50-TpG site
(a sign of possible PUVA induction), and three (17%) at
dipyrimidine sites opposite a 50-TpG sequence (a sign of
possible UV and/or PUVA induction). None of the Ha-ras
mutations detected in the PUVA keratoses were found in
normal skin tissue dissected from the same patients. In all
lesional and normal skin tissue samples from seven of nine
patients (patients A–F and H) (78%), however, a T:A ! C:G
base change at codon 27 was present. This change has
previously been described as a silent Ha-ras polymorphism
(Chapon et al, 1983; Hsieh et al, 1994; Kreimer-Erlacher
et al, 2001). In addition, 19 silent Ha-ras mutations (12 of UV
type, two of PUVA type, two of UV/PUVA type, and three of
other type) were found in the PUVA keratoses.
DNA sequencing analysis of both the p53 and the Ha-ras
gene was done for 25 of 28 PUVA keratoses; for the other
three samples, DNA was exhausted before it could be
analyzed for Ha-ras gene (Table IV). The sequencing data
revealed that seven of 25 PUVA keratoses (28%) had both
p53 and Ha-ras mutations, seven (28%) had only p53
mutations, four (16%) had only Ha-ras mutations, and seven
(28%) had neither mutation.
The UV ﬁngerprint portion of the p53 mutation spectrum
in PUVA keratoses was similar to that in actinic
keratoses from the general population The p53 muta-
tional spectrum in this study was compared with the p53
mutational spectrum derived from a pool of previous
sequencing studies of actinic keratoses from the general
population (Fig 1). PUVA keratoses exhibited a significantly
higher percentage of PUVA-type p53 mutations than did the
actinic keratoses (13 of 39 (33%) vs eight of 56 (14%);
Fisher’s exact test, p¼ 0.043). In addition, PUVA keratoses
exhibited a significantly higher percentage of these muta-
tions at 50-TpA sites (nine of 39 (23%) vs one of 56 (2%);
Fisher’s exact test, p¼0.0012). Conversely, PUVA kera-
toses exhibited a significantly lower percentage of all
mutations of the ‘‘other’’ type (three of 39 (8%) vs 16 of 56
(27%); Fisher’s exact test, p¼0.031). There was, however,
no statistically significant difference between PUVA kera-
toses and actinic keratoses in terms of the number of UV
fingerprint p53 mutations (22 of 39 (56%) vs 27 of 56 (48%);
Fisher’s exact test, p¼ 0.431).
Comparison of mutation types in PUVA keratoses and
PUVA-associated SCC at p53 and Ha-ras p53 and Ha-ras
mutations in PUVA keratoses were compared with those in
SCC from PUVA-treated psoriasis patients in terms of type,
number, and frequency (Fig 2). Regarding p53, PUVA-
associated SCC exhibited more PUVA-type mutations and
fewer UV-type mutations of the p53 gene than did PUVA
keratoses, although these differences did not reach
statistical significance (w2 test; p¼0.07 and p¼ 0.22,
respectively). Regarding Ha-ras, PUVA-associated SCC
exhibited significantly fewer UV-type mutations (six of 18
(33%) vs 13 of 18 (72%)) (Fisher’s exact test, p¼0.044) and
significantly more mutations of the ‘‘other’’ type (seven of 18
(39%) vs 0%) (Fisher’s exact test, p¼0.007) than did PUVA
keratoses. PUVA-associated SCC exhibited more PUVA-
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Table II. Types of mis-sense or non-sense p53 mutations found in PUVA keratoses
Tumor Exon Codon
Codon and
surrounding
sequencea Base change
Amino acid
change
Strand with
affected
pyrimidineb
Type of
mutation
A1 5 170 gACGg C ! T Thr ! Met T Other
9 322 aCCAc C ! T Pro ! Leu T UV/PUVA
B1 6 220 cTATg T ! A Tyr ! Aspn T PUVA
8 285 cCTCt C ! T Glu ! Lys NT UV
C3 7 238 gTGTa T ! G Cys ! Trp T PUVA
C5 7 234 cTACa T ! C Tyr ! His T PUVA
C6 4 61 cATCt C ! T Asp ! Aspn NT UV
4 89 cCCCt C ! T Pro ! Leu T UV
5 136 cCAAc C ! T Gln ! Stop T UV
5 139 c AAGa A ! T Lys ! Stop NT PUVA
5 140 gACCt C ! T Thr ! Ileu T UV
5 163 cTACa T ! C Tyr ! His T PUVA
7 234 cTACa T ! C Tyr ! His T PUVA
D1 5 136 gCCAa C ! T Gln ! Stop T UV/PUVA
D2 4 69 gGCTg C ! T Ala ! Val T UV
4 95 aTCTt C ! T Ser ! Phe T UV
4 98 cCCTt C ! T Pro ! Leu T UV
6 190 cCCTc C ! T Pro ! Ser T UV
6 205 gTATt T ! G Tyr ! Asp T PUVA
6 218 gCACc C ! T Val ! Met NT UV
6 220 cTATg T ! A Tyr ! Aspn T PUVA
E1 4 61 cATCt C ! T Asp ! Aspn NT UV
E1 7 226 aGCCa C ! T Gly ! Asp NT UV
8 282 cCGGc C ! T Arg ! Trp T UV
E2 4 61 cATCt C ! T Asp ! Aspn NT UV
5 149 tTCCa C ! T Ser ! Phe T UV
7 248 cCGGa C ! T Arg ! Trp T UV
E4 4 95 aTCTt C ! T Ser ! Phe T UV
9 323 aCTGg T ! C Leu ! Pro T PUVA
E5 6 190 cCCTc C ! T Pro ! Leu T UV
6 205 gTATt T ! G Tyr ! Asp T PUVA
6 217 cCACc C ! T Val ! Met NT UV
F2 7 249 gCCTc C ! G Arg ! Ser NT Other
F3 5 168 gCACa C ! T Arg ! Trp T PUVA
8 281/282 aGACCGGc CC ! TT None/Arg ! Trp T UV
G1 5 165 gCAGt C ! T Gln ! Stop T PUVA
H2 6 220 cTATg T ! A Tyr ! Aspn T PUVA
I1 4 95 aTCTt C ! T Ser ! Phe T UV
7 227 cTCTg C ! T Ser ! Phe T UV
aThe sequence is shown in 50 ! 30 direction for the strand (transcribed or nontranscribed) containing the pyrimidine(s) at mutation site. Nucleotides of
the affected codon are written in capital letters. Mutated bases are shown in bold letters. Multi- and dipyrimidines with UV-type mutations (C ! T
transitions) are underlined once; potential psoralen-binding sites (50-TpA, 50-ApT, 50-TpG/50-CpA, 50-TpT/50-ApA) with mutations (i.e., PUVA-type
mutations) are underlined twice.
bT, transcribed strand; NT, nontranscribed strand.
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type mutations of the Ha-ras gene than did PUVA keratoses,
although these differences did not reach statistical sig-
nificance (Fisher’s exact test, p¼0.40).
Discussion
Our sequence analysis study revealed that both the p53
gene and the Ha-ras gene were frequently mutated in PUVA
keratoses (Tables II–IV). Of particular interest were three
findings: (1) 56% of p53 mutations (22 of 39) and 72% of
Ha-ras mutations (13 of 18) occurred at dipyrimidine sites
and bore the UV fingerprint (C ! T or CC ! TT transitions);
(2) 33% of p53 mutations (13 of 39) and 11% of Ha-ras
mutations (two of 18) occurred at potential psoralen-binding
sites (50-TpA, 50-TpG, or 50-TpT DNA sequences) and were
thus potentially PUVA induced; and (3) the mutation spectra
of p53 and in particular Ha-ras did not show the typical
hotspot region distribution that had been previously
reported. For instance, most Ha-ras mutations were found
at other sites than the common oncogenic hotspots at
codon 12, 13, and 61. Concerning p53, however, more than
70% of the mutations (including the hotspot mutations at
codon 248 and 282) detected in this study have been
previously reported from other cancers, including cuta-
neous SCC (data not shown) (http://www.umd.necker.fr/).
The findings on mutation types agree with those of p53
sequencing studies of SCC (Nataraj et al, 1997; Wang et al,
1997; Stern et al, 2002) and BCC (Seidl et al, 2001; Stern
et al, 2002) from PUVA-treated psoriasis patients in which
many mutations bore the UV fingerprint (Fig 2). They also
agree with recent work from our own laboratory that
revealed that most Ha-ras mutations detected in PUVA-
associated SCC (Kreimer-Erlacher et al, 2001) and the
INK4a-ARF locus (Kreimer-Erlacher et al, 2003) also bore
the UV fingerprint. In most previous DNA sequencing
studies of genes in human PUVA-associated skin cancers
(Wang et al, 1997; Kreimer-Erlacher et al, 2001, 2003; Stern
et al, 2002), mutations classified as PUVA type were in the
minority. In fact, only one study so far has reported that
PUVA-type mutations outnumbered UV-type mutations in
human skin cancers (at the p53 gene) (Nataraj et al, 1997);
however, the authors later acknowledged that they mis-
takenly classified some mutations at 50-CpT sites as PUVA
type and so may have overestimated the presence of
PUVA-type mutations (Stern et al, 2002), Moreover, in a
study of mutations at the INK4a-ARF locus in PUVA-
associated SCC, no single mutation could be unambigu-
ously classified as PUVA induced (Kreimer-Erlacher et al,
2003).
A number of potential explanations for the high frequency
of UV fingerprint mutations in PUVA-associated tumors
have already been proposed (Nataraj et al, 1997; Wang
et al, 1997; Kreimer-Erlacher et al, 2001, 2003; Seidl et al,
2001; Stern et al, 2002). One of these is environmental and/
or therapeutic UV exposure. At first glance, our results seem
to support this explanation as (1) six of eight patients in this
study whose PUVA keratoses harbored UV-specific mis-
sense mutations at p53 and/or Ha-ras had a history of
therapeutic UVB exposure, and (2) several of the PUVA
keratoses we examined were taken from body sites
regularly exposed to natural sunlight (Table I). Moreover,
as the comparison of p53 mutational spectra in PUVA
keratoses from this study and actinic keratoses from the
general population revealed no significant difference in the
distribution of UV-type mutations (Fig 1), it is reasonable to
assume that the main initial, causative factor for both types
of lesions is UV exposure. When one compares our results
with those of previous studies in PUVA-associated SCC, the
frequency distributions of UV- and PUVA-type mutations of
the p53 gene are similar (Nataraj et al, 1997; Wang et al,
1997; Stern et al, 2002), whereas those of UV- and PUVA-
type mutations of the Ha-ras gene are not (Kreimer-Erlacher
et al, 2001). In fact, in this study, there were significantly
more UV-type mutations of the Ha-ras gene in PUVA
Figure 1
The UV fingerprint dominates the mutation spectra of the p53 gene
in PUVA keratoses and actinic keratosis from the general
population. p53 mutations detected in actinic keratoses from the
general population in several previous studies (for details see Materials
and Methods) were pooled and compared with those detected in our
collection of PUVA keratoses in terms of type and number. Note that in
this study and previous studies a few C ! T transitions occurred at
dipyrimidine sites, each opposite a 50-TpG sequence (a potential
psoralen-binding site) (see Table III). In this graph, these mutations are
represented in the blank column portions at the top of the column
marked C ! T and at the top of the column marked 50-TpG at
nondipyrimidine sites. As the origins of these mutations (UV or PUVA)
were ambiguous, they were considered separately in the mutational
spectrum analysis. When dipyrimidine sites and nondipyrimidine sites
were taken together, the proportion of p53 mutations at 50-TpA sites
was statistically significantly higher in PUVA keratoses than in actinic
keratoses from the general population (nine of 39 (23%) vs one of 56
(2%); Fisher’s exact test, p¼ 0.0012). There were significantly fewer
mutations of the ‘‘other’’ type in PUVA keratoses than in actinic
keratoses (three of 39 (8%) vs 16 of 56 (27%); Fisher’s exact test,
p¼0.031).
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keratoses than in PUVA-associated SCC (Fig 2). For several
reasons, however, we cannot totally rule out the possibility
that some of the mutations that we classified as UV type in
this study may have been indirectly caused by PUVA
exposure. First, it has been reported that stable oxidation
products of cytosine and thymidine induced by 8-methox-
ypsoralen (8-MOP) and UVA or by UVA alone can induce
C ! T transitions (Wang et al, 1998). Second, PUVA is
known to generate reactive oxygen species, which in turn
may also induce C ! T or CC ! TT transitions (Reid and
Loeb, 1993). As we have previously stated (Seidl et al,
2001), however, the hypothesis that exposure to PUVA or
UVA alone may result in UV-type mutations is strongly
contradicted by results of studies in cell cultures (Sage et al,
1993; Chiou and Yang, 1995; Gunther et al, 1995) and in
mice (Nataraj et al, 1996) in which UV-type mutations were
rarely if ever observed after PUVA exposure. Third,
fluorescent tubes used for PUVA therapy in Europe emit
small portions of radiation within the UVB range, which may
in turn cause UV-type mutations (Nataraj et al, 1997).
Our study also revealed that large percentages of
mutation-positive PUVA keratoses harbored two or more
mutations in the p53 gene (11 of 16; 69%) or in the Ha-ras
gene (five of 11; 45%) (Table IV). In several specimens, one
or more UV- and PUVA-type mutations occurred in both the
p53 and the Ha-ras gene. These results are consistent with
those of a previous study by Stern et al (2002), in which
44% of 55 human PUVA-associated nonmelanoma skin
cancers (including SCC and BCC) had multiple UV- and/or
PUVA-type p53 mutations. Multiple p53 mutations have also
been found in murine and human skin cancers and head
and neck cancers, and their significance in the context of
field cancerization has been previously discussed (Stern
et al, 2002, and references cited therein).
There is broad evidence that alterations in the p53 and
Ha-ras gene may cooperate in carcinogenesis in general (for
review, see Kreimer-Erlacher et al, 2001). The fact that in this
study p53 mutations and/or Ha-ras mutations were fre-
quently found in PUVA keratoses and that both genes were
mutated in more than a quarter of the cases (Table IV)
suggest that they also may cooperate in the formation
of PUVA keratoses. Greenblatt et al (1994) found that
approximately 90% of all p53 mutations in cancers occur
between exons 5 and 8 at the hydrophobic region (DNA-
binding site) of the p53 gene. In our study, we found that
nine of 39 mis-sense/non-sense mutations (23%) occurred
in the nonconserved domain of exon 4 (codons 61–89), nine
(23%) in the conserved domain III of exon 5 (codons 136–
170), eight (21%) in the nonconserved domain of exon 6
(codons 205–220), seven (18%) in the conserved domain IV
of exon 7 (codons 226–249), three (8%) in the conserved
domain V of exon 8 (codons 281–285), and two (5%) in the
nonconserved domain of exon 9 (codons 322 and 323) in
the basic C-terminus, which contains the oligomerization
Table III. Types of mis-sense and non-sense Ha-ras mutations found in PUVA keratoses
Tumor Exon Codon
Codon and
surrounding
sequencea Base change
Amino acid
change
Strand with
affected
pyrimidineb
Type of
mutation
A1 1 13 cACCg C ! T Gly ! Asp NT UV
2 70 cCAGt C ! T Gln ! Stop T UV/PUVA
3 105 aGTCc C ! T Asp ! Asn NT UV
3 135 tTCGg C ! T Arg ! Gln NT UV
C2 4 178 gGCCa C ! T Gly ! Ala NT UV/PUVA
C4 2 48 cCCCa C ! T Gly ! Arg NT UV/PUVA
C5 4 177 cACTc C ! T Ser ! Asn NT UV
C6 1 6 gCTGg T ! C Leu ! Pro T PUVA
1 8 cCACc C ! T Val ! Met NT UV
4 173 cCCTc C ! T Pro ! Ser T UV
D1 1 8 cCACc C ! T Val ! Met NT UV
3 127 aTCTc C ! T Ser ! Phe T UV
E4 1 20 gACCa C ! T Thr ! Ile T UV
F3 4 173 cCCTc C ! T Pro ! Leu T UV
F5 2 45 tGACc C ! T Val ! Ileu NT UV
2 62 cCTCc C ! T Glu ! Lys NT UV
H1 3 122 gTGCa C ! T Ala ! Thr NT PUVA
H2 2 44 cCACc C ! T Val ! Met NT UV
aThe sequence is shown in 50 ! 30 direction for the strand (transcribed or nontranscribed) containing the pyrimidine(s) at mutation site. Nucleotides of
the affected codon are written in capital letters. Mutated bases are shown in bold letters. Multi- and dipyrimidines with UV-type mutations (C ! T
transitions) are underlined once; potential psoralen-binding sites (50-TpA, 50-ApT, 50-TpG/50-CpA, 50-TpT/50-ApA sites) with mutations (i.e., PUVA-type
mutations) are underlined twice.
bT, transcribed strand; NT, nontranscribed strand.
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domain that is essential in forming the active tetrameric p53
complexes that bind DNA (Table II). Particularly, mutations
in conserved p53 domains have been proposed to abrogate
p53 tumor suppressor activity and thereby give the
mutation-harboring cells a proliferative growth advantage.
The p53 mutations that we found in PUVA keratoses at
codon 248 (exon 7) (one C ! T transition) and at codon
281/282 (exon 8) (one C ! T transition and one CC ! TT
transition) are well-known hotspots for mutation in skin
cancers and frequently in other cancers as well. Although
the exact significance of Ha-ras mutations occurring at sites
other than the well known codons 12, 13, and 61 is not clear
at present (Zarbl et al, 1985; Trahey and McCormick, 1987),
at least some of the Ha-ras mutations that we observed in
this study may affect the function of the p21ras protein. For
instance, the mutation at codon 8 observed in two PUVA
keratoses (C6 and D1) (Table III) has been implicated in
guanine nucleotide binding (Lewin et al, 1997). The
replacement of amino acid 13 observed in another PUVA
keratosis (A1) is part of the loop 1 region (amino acids
13–17). The replacement of Gly-13 by valine activates the
transforming potential of the protein (Pai et al, 1989).
Normally, the b-phosphate group of the bound GDP
molecule interacts extensively with residues 13 to 17 of
the p21 molecule (Tong et al, 1991). In our case, Gly-13 was
replaced by asparagine. Meanwhile, amino acid changes
observed in two other PUVA keratoses (F5 and A1) at
positions 62 and 70 concern the switch II region, spanning
amino acids 60 to 76. The switch II region undergoes
significant structural changes when GTP replaces GDP
during the activation of the p21ras protein (Milburn et al,
1990). In PUVA keratosis F5, Glu-62 was replaced by lysine.
Gln-61 and Glu-62 are highly conserved in the small
nucleotide binding proteins, and Glu-63 is conserved in all
ras gene products, suggesting that the switch II region is
important for the function of p21ras proteins (Pai et al,
1990).
Alternatively, however, many Ha-ras mutations found in
this study may have occurred as an epiphenomena (without
functional relevance) and their formation may have taken
place causally unrelated to the formation of PUVA kera-
toses. For instance, an overall effect of decreased DNA
repair capacity, e.g., caused by dysfunction of genes such
as p53 (Santamaria et al, 2002), may have caused at least
some of the Ha-ras mutations. This hypothesis is supported
by (1) the fact that all but one Ha-ras mutations were found
at other sites than the well-known oncogenic hotspots at
codons 12, 13, and 61 (Zarbl et al, 1985; Trahey and
McCormick, 1987), and (2) the presence of a high number of
silent Ha-ras mutations in the PUVA keratoses.
Table IV. Presence of Ha-ras and p53 mis-sense or non-sense
mutations in PUVA keratoses
Tumor
No. and type of
p53 mutations
No. and type of
Ha–ras mutations
A1 1 UV/PUVA, 1 Other 3 UV, 1 UV/PUVA
B1 1 UV, 1 PUVA –
C1 – –
C2 – 1 UV/PUVA
C3 1 PUVA –
C4 – 1 UV/PUVA
C5 1 PUVA 1 UV
C6 4 UV, 3 PUVA 2 UV, 1 PUVA
D1 1 UV/PUVA 2 UV
D2 4 UV, 2 PUVA, 1 Other –
D3 – –
E1 3 UV –
E2 3 UV –
E3 – –
E4 1 UV, 1 PUVA 1 UV
E5 2 UV, 1 PUVA NE
E6 – NE
F1 – –
F2 1 Other –
F3 1 UV, 1 PUVA 1 UV
F4 – –
F5 – 2 UV
G1 1 PUVA –
G2 – –
H1 – 1 PUVA
H2 1 PUVA 1 UV
I1 2 UV NE
J1 – –
NE, not examined because no DNA was available for analysis of
Ha-ras.
Figure2
Comparison of mutational spectra of PUVA keratoses and PUVA-
associated SCC. Pooled data from the literature on p53 (Nataraj et al,
1997; Wang et al, 1997) and Ha-ras (Kreimer-Erlacher et al, 2001) in
PUVA-associated SCC were compared with data from this study on
p53 and Ha-ras mutations in PUVA keratoses. Regarding the p53 gene,
there were no significant differences in any mutation type between
PUVA-associated SCC and PUVA keratoses. Regarding the Ha-ras
gene, there were significantly fewer UV-type mutations in PUVA-
associated SCC than in PUVA keratoses (six of 18 (33%) vs 13 of 18
(72%); Fisher’s exact test, p¼ 0.044); however, there were significantly
more mutations of the ‘‘other’’ type in PUVA-associated SCC than in
PUVA keratoses (seven of 18 (39%) vs 0%; Fisher’s exact test,
p¼ 0.007). Mutation types are defined in Table II.
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An important observation in this study was that most
PUVA-type mutations (nine of 13; 69%) at the p53 gene
occurred at 50-TpA DNA sequences. For example, three
patients (patients B, D, and H) had the same fingerprint
mutation at p53, namely a T ! A transversion at a 50-TpA
site in exon 6 (codon 220), suggesting that this may be a
hotspot codon for PUVA-type mutations. This predomi-
nance of mutations at 50-TpA DNA sequences is consistent
with results of cell culture studies in which psoralen
preferentially bound to 50-TpA sequences and suggests
that such sequences are primary targets for PUVA
carcinogenesis (Sage 1993; Sage et al, 1993; Yang et al,
1994; Chiou and Yang, 1995). Also, p53 mutations were
found primarily at 50-TpA sequences in SCC induced in
mice by chronic topical PUVA treatment (Nataraj et al,
1996). In this study, however, PUVA-type mutations were
also (but less frequently) observed at or opposite
50-TpG sequences on the p53 gene (five mutations) and
the Ha-ras gene (two mutations). This finding adds to the
knowledge gained from previous mutational studies of p53
(Nataraj et al, 1997; Seidl et al, 2001), Ha-ras (Kreimer-
Erlacher et al, 2001), and the INK4a-ARF locus (Kreimer-
Erlacher et al, 2003) of PUVA-associated skin cancers from
psoriasis patients, in which most PUVA-type mutations
were observed at 50-TpG sequences. Possible reasons for
the frequent occurrence of mutations at 50-TpG sequences
in human PUVA-associated skin tumors have been pre-
viously discussed in detail (Nataraj et al, 1997; Wang et al,
1997; Kreimer-Erlacher et al, 2001, 2003; Seidl et al, 2001).
In brief, some have speculated that the application of too
high and, thus, clinically irrelevant UVA doses in PUVA cell
culture mutagenesis studies, the different processing of
psoralen photoadducts under in vitro conditions, or both
might produce mutational spectra different from those seen
in human skin cancers.
In this study of PUVA keratoses, a small number of
mutations at p53 (two of 39; 5%) could not be classified as
either the UV or PUVA type and so were classified as
‘‘other.’’ As mentioned earlier and as was the case in this
study (Table I), psoriasis patients often have a history of
exposure to other potentially carcinogenic treatment
agents, including ionizing radiation, methotrexate, arsenic,
and topical tar. One or more of these agents, or perhaps
some as yet unidentified agent or agents, may have been
responsible for these ‘‘other’’ mutations in this study.
Nevertheless, our results demonstrate that p53 and Ha-
ras are often mutated in PUVA keratoses and that the
resulting mutations may cooperate in the formation of those
lesions. Most of the Ha-ras and p53 mutations we observed
were of the UV type, which suggests that environmental
and/or therapeutic UV exposure may be the major primary
causative factor in PUVA keratoses. PUVA itself seems to
play a smaller, although direct, role in causing these muta-
tions. As previously suggested (Kreimer-Erlacher et al,
2003), however, it may be that it is through nonmutational
effects such as PUVA-induced tumor promotion and
immunosuppression (Strauss et al, 1980; Kripke et al,
1982) rather than direct mutagenic effects that PUVA
promotes skin carcinogenesis after long-term treatment
with high cumulative UVA doses. Moreover, PUVA-induced
apoptosis (Santamaria et al, 2002) in normal keratinocytes
and the lack of apoptosis in p53 mutants cells may also
have the capacity to promote strongly the development of
PUVA keratoses and subsequent SCC. Indeed, the similar
mutational spectra of PUVA-associated SCC and PUVA
keratoses indirectly suggest that PUVA keratoses may be
precursors of at least some SCC. A quarter of our PUVA
keratoses showed no mutation in either the p53 or Ha-ras
gene. This observation raises the possibility that these
lesions, if not mutated in other key cancer genes, for
instance such as INK4a-ARF locus (Kreimer-Erlacher et al,
2003), may have no capacity to progress towards a
malignant tumor type.
Materials and Methods
Patients and tumors Twenty-eight squamous keratoses from 10
PUVA-treated psoriasis patients (four females and six males) were
available for DNA mutational analysis. All 28 were randomly
selected from an archive of paraffin-embedded lesions previously
identified and removed in a PUVA follow-up study at the
Department of Dermatology of the Karl-Franzens-University (Graz,
Austria) (Scho¨llnast, 1997). All of the selected lesions bore the
clinical and histologic features of PUVA keratosis previously
described by Van Praag et al (1993). The patients’ demographics,
tumor characteristics, and PUVA treatment data are shown in
Table I. According to Australian law, no IRB approval was
necessary specifically for the study at the time when the study
was performed.
DNA extraction DNA was extracted from the 28 lesions as
follows. First, the paraffin-embedded samples were macrodis-
sected or microdissected or both in order to (1) eliminate
nonlesional tissue adjacent to the PUVA keratoses, and (2) obtain
normal tissue from each sample for control polymerase chain
reaction–single-strand conformation polymorphism (PCR–SSCP)
and sequencing studies. Tissues were then sectioned into 7 to
10 mm thick slices and placed on SuperFrost Plus slides (Menzel,
Braunschweig, Germany), deparaffinized with xylene for 10 min
and ethanol for 10 min, air dried, and dampened in deionized
water. Next, tissues were scraped off the slides, suspended in 50
to 100 mL of a solution containing 0.1 M Tris–HCl (pH 8.0) and 1 mg
proteinase K per mL, incubated at 551C overnight, boiled for
10 min, and finally stored at 201C until analysis.
PCR–SSCP analysis Once extracted, the lesional DNA was
subjected to PCR–SSCP as follows. Oligonucleotide primers for
Ha-ras exons 1 and 2 and exons 3 and 4 and for p53 exons 4 to 9
were used in PCR reactions, as previously described (Kreimer-
Erlacher et al, 2001; Seidl et al, 2001). The template for PCR
consisted of 4 mL of DNA lysate in a 50 mL solution containing 10
mM Tris–HCl, pH 8.3; 50 mM KCl; 1.5 mM MgCl2 (for PCR involving
Ha-ras exons 1 and 2 and p53 exons 4–9) or 1 mM MgCl2 (for PCR
involving Ha-ras exons 3 and 4); 200 mM of each deoxyribonucleo-
side triphosphate; 10 pM of the upstream primer; 10 pM of the
downstream primer; and 2.5 U of AmpliTaq Gold Polymerase
(Perkin Elmer, Vienna, Austria). Reaction mixtures were subjected
to 40 cycles of amplification in a Perkin Elmer Thermocycler Model
9700 (Perkin Elmer, Foster City, California). Each cycle consisted of
denaturation at 941C for 45 s; annealing at 581C (Ha-ras exons 1
and 2), 551C (Ha-ras exons 3 and 4), or 601C (p53 exons 4–9) for 30
s; and polymerization at 721C for 30 s. Before the first cycle, tubes
containing PCR mixtures were incubated for 12 min at 941C; after
the last cycle, for 7 min at 721C. Tubes without template DNA were
included in each PCR run as negative controls for potential
contamination of PCR reactions. For SSCP analysis, PCR products
were purified by gel electrophoresis on 3% Metaphor agarose gels
(BioWhittaker Molecular Applications, Rockland, Maine) and
subsequent gel extraction (Qiagen, Hilden, Germany). Samples
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were then applied to a commercially available gel (GeneGel Excel
12.5 cm/24 slots; Pharmacia Biotech, Uppsala, Sweden) and run
for 1 h, 30 min at 51C (for Ha-ras exons 1 and 3), 101C (for p53
exons 7–9), 151C (for Ha-ras exon 2 and p53 exon 6), or 201C (for
Ha-ras exon 4 and p53 exons 4 and 5). The running conditions
were as follows: voltage, 600 V; current, 25 mA; power, 15 W.
Finally, the gels were stained using a DNA silver staining kit
(Pharmacia Biotech). PCR–SSCP was performed at least twice per
sample.
Direct sequencing Each DNA sample shown by PCR–SSCP
analysis to contain aberrant (i.e., mutated) bands was then
subjected to direct sequencing of its DNA. In brief, 60 ng of each
tumor’s DNA was amplified with 3.2 pM of primer (PE Applied
Biosystems, Weiterstadt, Germany). The amplified products were
then precipitated and analyzed on an ABI Prism 310 system (Perkin
Elmer). Human placental DNA was simultaneously analyzed to rule
out PCR-generated mutations. Sequencing analysis was per-
formed at least twice per sample, and the presence of a mutation
or base change was always confirmed by sequencing the opposite
DNA strand.
Comparisons of mutational spectra and mutation types The
p53 mutational spectrum of our collection of PUVA keratoses was
compared with the p53 mutational spectrum derived from a pool of
previous sequencing studies of actinic keratoses from the general
population (Nelson et al, 1994; Taguchi et al, 1994; Ziegler et al,
1994; Park et al, 1996). No such comparison was made for Ha-ras
because we were unable to find any applicable published data via
a search of PubMed (www.ncbi.nlm.nih.gov). In addition, however,
the p53 and Ha-ras mutational spectra of our collection of PUVA
keratoses were compared with those derived from previous
sequencing studies of SCC from PUVA-treated psoriasis patients
(Nataraj et al, 1997; Wang et al, 1997; Kreimer-Erlacher et al, 2001).
The type, number, and frequency of mutations observed in our
collection of PUVA keratoses (classified by origin as UV, PUVA, UV/
PUVA, or other) were compared with the type, number, and
frequency of mutations in actinic keratoses from the general
population or SCC from PUVA-treated psoriasis patients.
Statistical analysis Differences between groups of subjects and
lesions in terms of type and number of mutations were analyzed for
statistical significance using Fisher’s exact test or the w2 test in the
StatView statistical analysis program version 5.0.1 (SAS Institute
Inc., Cary, North Carolina). p  0.05 was considered statistically
significant.
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